

A Clinical Study of AK0610

NCT06996704

| | |
|-------------------|--|
| Status | RECRUITING |
| Phase | Phase 1 |
| Sponsor | Shanghai Ark Biopharmaceutical Co., Ltd. |
| Enrollment | 136 participants |

Key Eligibility Criteria

Inclusion (5)

- Participants aged 18 - 50 (both males and females)
- Males weighing ≥ 50 kg, females weighing ≥ 45 kg, and BMI 18-28 kg/m².
- Assessed by the investigator to be in good health with no clinically significant abnormalities.
- Use of highly effective contraception within 1 year of administration.
- Voluntary participation in clinical research and signing of written informed consent.

Exclusion (16)

- Clinically significant cardiovascular, respiratory, hepatic, renal, hematologic (e.g., bleeding disorders), gastrointestinal, endocrine, immunologic, dermatologic, neurologic, psychiatric system disorders, or any other condition that, in the opinion of the Investigator, may jeopardize subject safety or validity of the study results, or that may result in the inability of the subject to complete the study in accordance with the protocol.
- Active malignancy and/or a history of malignancy (except for basal cell carcinoma of the skin that has been treated without evidence of recurrence)
- History of congenital or acquired immunodeficiency.
- Acute illness, such as fever, infectious disease, diarrhea, etc., occurring within 1 week prior to the subject's first dose.
- Major surgery within 3 months prior to screening or major surgery planned within 1 year of study drug administration.
- ... and 11 more (see full listing online)

Locations (1 total)

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital , Jinan, Shandong, China